SNCA: Seneca Biopharma, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Seneca Biopharma, Inc.

NASDAQ:SNCA

SummaryFactSheetFinancial
Notice
Stock data is unavailable or the company’s delisted.
Price
$4.60
Loss Chance
58.0%
1.09JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
AbbVie
NYSE:ABBV
6.05
$227.73
136.78%
Alexion Pharmaceuticals
NASDAQ:ALXN
6.89
$182.50
52.20%
Biogen
NASDAQ:BIIB
5.83
$200.05
16.72%
Emergent BioSolutions
NYSE:EBS
3.64
$8.32
83.60%
Gilead Sciences
NASDAQ:GILD
6.77
$125.59
5.10%
Jitta Factors
Growth Opportunity (11)
Recent Business Performance (11)
Financial Strength (48)
Return to Shareholders (0)
Competitive Advantage (16)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2020
Operating MarginDeclined
Recent Business PerformanceEarning decline 112.81% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
1.09
100.00%
2.12
311.43%
2.12
311.43%
6.89
52.20%
COMPANY DESCRIPTION
As of April 27, 2021, Seneca Biopharma, Inc. was acquired by Leading BioSciences, Inc., in a reverse merger transaction. Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company’s stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
www.senecabio.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.